Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

Topics

Novo Nordisk shares tumble as weight-loss drug trial data disappoints

Obesity drug CagriSema misses goal of 25% body weight reduction
Financial Times - 8h
Micron’s stock may see its worst day since 2020. Why the bulls are still upbeat.

Analysts are largely upbeat on Micron’s stock, pointing to an upbeat AI narrative while noting that pressures on consumer markets shouldn’t be much shock to Wall Street.
MarketWatch - 1d
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.

In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.
The New York Times - 1d
Why the investor craze for Ozempic and rival weight-loss drugs may resume next year

Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said
MarketWatch - 4d
In shift, RFK Jr. now says weight-loss drugs 'have a place'

His remarks come days before he holds confirmation meetings with GOP senators.
ABC News - Dec. 12
On Ozempic? Big Food Makers Have a New Label for You

Conagra Brands is adding “GLP-1 friendly” to packaging on Healthy Choice frozen meals to woo users of weight-loss drugs.
The Wall Street Journal - Dec. 12
Alphabet’s stock having best 2-day run in a decade as the good news keeps coming

Google parent Alphabet’s stock is having its best two-day run in nine years amid good news on the quantum-computing and Waymo fronts.
MarketWatch - Dec. 11
Beneath the hood, stocks just suffered their worst day of the year. Some are worried.

Momentum stocks quietly just had their worst day of the year. History points to a mixed experience when that happens.
MarketWatch - Dec. 10
Millions will have to wait up to 12 years for NHS weight-loss drug

Fears that giving 3.4 million people immediate access to new weight-loss drug could overwhelm NHS.
BBC News - Dec. 5

Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints

Topics

Related

Novo Nordisk shares tumble as weight-loss drug trial data disappoints

Micron’s stock may see its worst day since 2020. Why the bulls are still upbeat.

Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.

Why the investor craze for Ozempic and rival weight-loss drugs may resume next year

In shift, RFK Jr. now says weight-loss drugs 'have a place'

On Ozempic? Big Food Makers Have a New Label for You

Alphabet’s stock having best 2-day run in a decade as the good news keeps coming

Beneath the hood, stocks just suffered their worst day of the year. Some are worried.

Millions will have to wait up to 12 years for NHS weight-loss drug

More from MarketWatch

Oil prices score weekly losses on strong dollar, China demand worries

FedEx’s freight-unit spinoff offers ‘early Christmas’ to Wall Street

Act now to sell losing stocks, offset gains and work around the ‘wash-sale’ rule

A laptop you can repair yourself — and other smart tech gifts for the holidays

Warren Buffett ignores Wall Street, buys more stock in this oil-and-gas company